Crossing the Blood-Brain Barrier? FDA Requires an Abuse Potential Assessment
June 28, 2018 - Toronto ON CAXtalks
fbonilla@xtalks.com
Phone:4169776555
In this session, presenters will focus on the role of an abuse potential assessment (also referred to as the Controlled Substances Act 8-factor analysis) in the development of CNS-active drugs and related interactions with FDA and DEA.
This website uses cookies to ensure you get the best experience on our website. Learn more